(UroToday.com) Following androgen deprivation therapy (ADT) which was introduced decades prior, the TAX-327 trial of docetaxel for patients with metastatic castration-resistant prostate cancer was the first to demonstrate a survival advantage for systemic treatment in prostate cancer. Since then, docetaxel has proven survival benefit for men with metastatic castration-sensitive disease. However, the benefit of docetaxel in men with non-metastatic prostate cancer is less clear. In particular, pooled results of six randomized controlled trials have suggested an overall survival benefit without a prostate cancer-specific mortality benefit and, thus, docetaxel is not recommended to treat unfavourable-risk non-metastatic prostate cancer. In the Prostate, Testicular, Penile Poster Discussion session at the 2021 American Society of Clinical Oncology 2021 Annual Meeting, Dr. Anthony D’Amico presented results of a randomized controlled trial (NCT00116142) examining the role of docetaxel with radiation therapy and androgen deprivation therapy in men with non-metastatic unfavorable-risk prostate cancer.